Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Psychiatric disorders – page 41

  • 546 clinical trials
  • 252 recruiting
  • 147 conditions
  • 26 countries

Conditions in this area

147 conditions with trials, the busiest first

Dementia Alzheimer's type87Major depression57Schizophrenia39Depression35Narcolepsy19Cognitive disorder18Bipolar disorder16Autism spectrum disorder15Insomnia15Post-traumatic stress disorder14Psychotic disorder14Drug use disorder13Alcohol use disorder12Attention deficit hyperactivity disorder9Dementia9Obstructive sleep apnoea syndrome9Brain injury8Irritable bowel syndrome8Phenylketonuria8Bipolar I disorder7Drug dependence7Hypersomnia7Lennox-Gastaut syndrome7Anorexia nervosa6+123

Clinical trials in Psychiatric disorders

546 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

546 clinical trials

Schizophrenia

Not recruiting

Study on Tolcapone for Improving Cognitive Symptoms in Patients with Long-Standing Schizophrenia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Tolcapone
  • Sponsor:Clinica Universidad De Navarra

Obstructive sleep apnoea syndrome

Not recruiting

Study of Nacystelyn for Patients with Obstructive Sleep Apnea

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nacystelyn
  • Sponsor:Laboratoires S.M.B.

Seizure+1

Not recruiting

Study on the Effects of Psilocybin for Patients with Psychogenic Non-Epileptic Seizures (PNES)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Psilocybine
  • Sponsor:Centre Hospitalier Universitaire De Nimes

Cognitive disorder+1

Not recruiting

Study on RL-007 for Improving Cognitive Impairment in Schizophrenia Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:(2R,3S)-2-Amino-3-Hydroxy-3-Pyridin-4-Yl-1-Pyrrolidin-1-Ylpropan-1-One (2R,3R)-2,3-Dihydroxybutanedioic Acid
  • Sponsor:Recognify Life Sciences Inc.

Hyperphagia

Not recruiting

Study on Carbetocin Nasal Spray for Reducing Uncontrollable Hunger in Patients with Prader-Willi Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Carbetocin
  • Sponsor:Acadia Pharmaceuticals Inc.

Dementia Alzheimer's type

Not recruiting

Study of ACP-204 for Treating Psychosis in Adults with Alzheimer's Disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Acp-204 Tartrate
  • Sponsor:Acadia Pharmaceuticals Inc.

Neurodevelopmental disorder

Not recruiting

Study on the Safety and Feasibility of Oral Zinc Acetate Dihydrate for Patients with GNAO1-Related Disorders

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Zinc Acetate Dihydrate
  • Sponsor:University Of Cologne

Dementia Alzheimer's type

Not recruiting

Study of BAN2401 (lecanemab) in people with early stage Alzheimer's disease to evaluate its effectiveness in preventing disease progression

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:Eisai Limited

Dementia with Lewy bodies

Not recruiting

Study on Neflamapimod for Patients with Dementia with Lewy Bodies

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Neflamapimod
  • Sponsor:Eip Pharma Inc.

Schizophrenia

Not recruiting

Study of KarXT (trospium chloride and xanomeline tartrate) in patients with inadequately controlled schizophrenia symptoms

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Karuna Therapeutics Inc.

Study on the Effects of NMRA-335140 for Adults with Major Depressive Disorder

Not recruiting
Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.

Study on Long-term Safety and Effectiveness of NMRA-335140 for Patients with Major Depressive Disorder

Not recruiting
InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Psychiatric disorders trials.

Sodium Chloride25 clinical trialsTrospium Chloride17 clinical trialsXanomeline Tartrate16 clinical trialsCannabidiol15 clinical trialsDry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol14 clinical trialsFlorquinitau (18F)14 clinical trialsOxytocin13 clinical trialsAripiprazole12 clinical trialsFlorbetaben (18F)12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.